Anna S Geraedts1, Johanna M van Dongen, Annet M Kleiboer, Noortje M Wiezer, Willem van Mechelen, Pim Cuijpers, Judith E Bosmans. 1. From the Department of Clinical Psychology and EMGO Institute for Health and Care Research (Drs Geraedts, Kleiboer, and Cuijpers), VU University Amsterdam; Body@Work Research Center Physical Activity, Work and Health (Drs Geraedts, Kleiboer, Wiezer, van Mechelen, and Cuijpers), TNO-VU-VUmc, Amsterdam; Department of Health Sciences and EMGO Institute for Health and Care Research (Drs van Dongen and Bosmans), VU University Amsterdam; TNO (Dr Wiezer), Hoofddorp; and Department of Public and Occupational Health Psychology and EMGO Institute for Health and Care Research (Dr van Mechelen), VU University Medical Center, Amsterdam, the Netherlands.
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of a Web-based guided intervention compared with care as usual for employees with depressive symptoms. METHODS: A total of 231 employees with depressive symptoms were randomized. Data were collected at baseline, 8 weeks, 6 months, and 12 months. Analyses were conducted from the societal and employer's perspective. RESULTS: At 12 months, a significant intervention effect on depressive symptoms was found. At a willingness to pay of 0 (€/unit of effect), the intervention's probabilities of cost-effectiveness were 0.62 (societal perspective) and 0.55 (employer's perspective). There was a 0.63 probability that the intervention resulted in a positive financial return for the employer. CONCLUSIONS: The intervention's cost-effectiveness with regard to depressive symptoms depends on the willingness to pay of societal and company decision makers as well as the probability of cost-effectiveness that they consider acceptable. The intervention is not cost-saving to the employer.
RCT Entities:
OBJECTIVE: To evaluate the cost-effectiveness of a Web-based guided intervention compared with care as usual for employees with depressive symptoms. METHODS: A total of 231 employees with depressive symptoms were randomized. Data were collected at baseline, 8 weeks, 6 months, and 12 months. Analyses were conducted from the societal and employer's perspective. RESULTS: At 12 months, a significant intervention effect on depressive symptoms was found. At a willingness to pay of 0 (€/unit of effect), the intervention's probabilities of cost-effectiveness were 0.62 (societal perspective) and 0.55 (employer's perspective). There was a 0.63 probability that the intervention resulted in a positive financial return for the employer. CONCLUSIONS: The intervention's cost-effectiveness with regard to depressive symptoms depends on the willingness to pay of societal and company decision makers as well as the probability of cost-effectiveness that they consider acceptable. The intervention is not cost-saving to the employer.
Authors: Lina Gega; Dina Jankovic; Pedro Saramago; David Marshall; Sarah Dawson; Sally Brabyn; Georgios F Nikolaidis; Hollie Melton; Rachel Churchill; Laura Bojke Journal: Health Technol Assess Date: 2022-01 Impact factor: 4.014
Authors: AnneClaire G N M Zaman; Kristien M A J Tytgat; Jean H G Klinkenbijl; Monique H W Frings-Dresen; Angela G E M de Boer Journal: BMC Cancer Date: 2016-05-10 Impact factor: 4.430
Authors: Spyros Kolovos; Johanna M van Dongen; Heleen Riper; Claudia Buntrock; Pim Cuijpers; David D Ebert; Anna S Geraedts; Robin M Kenter; Stephanie Nobis; Andrea Smith; Lisanne Warmerdam; Jill A Hayden; Maurits W van Tulder; Judith E Bosmans Journal: Depress Anxiety Date: 2018-01-12 Impact factor: 6.505
Authors: Claudia Buntrock; Fanny Kählke; Filip Smit; Matthias Berking; Dirk Lehr; Elena Heber; Burkhardt Funk; Heleen Riper; David Daniel Ebert Journal: JMIR Ment Health Date: 2019-05-15
Authors: Anna Holst; Cecilia Björkelund; Alexandra Metsini; Jens-Henrik Madsen; Dominique Hange; Eva-Lisa L Petersson; Maria Cm Eriksson; Marie Kivi; Per-Åke Å Andersson; Mikael Svensson Journal: BMJ Open Date: 2018-06-14 Impact factor: 2.692